Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 1st Preview)
-
Sanofi and Regeneron expand long-acting immunology pipeline
Sanofi and Regeneron expanded their long-standing antibody alliance with a new deal worth up to $8 billion, centered on developing next-generation long-acting immunology drugs that build on the same pathways behind Dupixent (dupilumab). Under the agreement, Regeneron receives $1 billion upfront, with up to $7 billion tied to development, regulatory and commercial milestones. The companies will share development and costs 50:50 and split future profits globally on a 50:50 basis, with Regeneron leading R&D and Sanofi owning global commercialization. The collaboration adds multiple long-acting candidates, including REGN20423 (an IL-13 monoclonal antibody in Phase 1 for atopic dermatitis), along with a long-acting IL-4xIL-13 bispecific and additional long-acting antibodies targeting IL-4 and IL-4 receptor alpha. Sanofi also gains an option framework around Regeneron bringing in lunsekimig after a Phase 3 readout.
-
HHS launches SURPASS and ARPA-H initiatives to speed clinical trials
The U.S. Department of Health and Human Services unveiled new programs designed to speed and modernize clinical development, citing intensifying global competition and operational bottlenecks that slow trial timelines. The centerpiece is SURPASS, funded and launched through ARPA-H, which aims to shift from traditional, phase-by-phase trials toward “simulation-augmented, real-time platform adaptive seamless trials.” HHS also announced three ARPA-H projects targeting clinical trial enrollment, building nationwide data infrastructure, and empowering patients involved in research. The move reflects data showing China’s growing share of early-stage trials and a push to make the U.S. more attractive for sponsors. It follows FDA efforts to streamline early trial execution, including Operation Trialblazer, and comes after European drugmakers warned they were losing ground to faster-loading trial environments.
-
Hibernating hamsters reveal histone rewiring during torpor
New research highlights how Syrian hamsters survive winter torpor by changing chromatin structure without rewriting their DNA sequence. The study focuses on histone modifications that help cells shift into a low-metabolic state and then return to normal activity after hibernation. The work adds mechanistic detail to how mammalian cells can temporarily tolerate conditions that would otherwise be lethal, including major drops in body temperature and metabolic rate. By emphasizing histone dynamics, the findings suggest that genome accessibility—not gene-code changes—may be key to rapid physiological reversibility. For biotech audiences, the biology provides an experimentally grounded example of how epigenetic control can support stress tolerance and recovery, potentially informing future translational work in organ preservation and critical care.
-
Regulatory turnaround attempt: Atara and Pierre Fabre resubmit Ebvallo
Atara Biotherapeutics and Pierre Fabre Pharmaceuticals said they have resubmitted to the FDA for Ebvallo (tabelecleucel) after earlier rejections, as the partners seek approval for a post-transplant complication driven by Epstein-Barr virus. The therapy was initially developed for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The companies previously received complete response letters, including one tied to manufacturing issues and a later rejection related to the adequacy and interpretability of pivotal clinical data. The new resubmission is expected to be treated as a Class 2 BLA resubmission by analysts, which would align with a potential target action date in 2027. The companies argue the regulatory position has shifted again and that additional data included in the resubmission better supports the proposed path forward.
-
Lilly exits Foghorn synthetic lethality collaboration
Eli Lilly is ending its collaboration with Foghorn Therapeutics in synthetic lethality, according to the latest reporting that the biotech has cut headcount by 40% after the partnership was culled over disappointing early data. The companies are dropping their Phase 1 synthetic lethality drug development efforts, and Foghorn’s restructuring reflects a broader pattern of selective portfolio trimming as investors and pharma push harder for early clinical signals. For the sector, the decision underscores the risk profile of early synthetic lethality strategies and the increasing scrutiny applied to whether mechanistic programs translate into reproducible human biology.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.